Boston Scientific Completes Acquisition of CryoCor

NATICK, Mass. and SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX) and CryoCor, Inc. (Nasdaq: CRYO) today
announced that Boston Scientific has completed its acquisition of CryoCor.
The transaction follows the definitive agreement announced on April 16. Under
the terms of the transaction, all remaining outstanding CryoCor shares are
entitled to receive $1.35 per share in cash, for a total of approximately
$17.6 million. CryoCor is now an indirect, wholly-owned subsidiary of Boston
Scientific.
About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.
Boston Scientific's Electrophysiology business is a leader in cardiac
ablation products designed to treat common cardiac arrhythmias. Its line of
Blazer(TM), Blazer XP(TM) and Chilli II(TM) products are used to treat
arrhythmias such as Atrial Flutter and Ventricular Tachycardia. The
Electrophysiology business also supplies a complete line of multi-electrode
diagnostic catheters, ultrasound (ICE) catheters and accessories.
About CryoCor, Inc.
CryoCor is a medical technology company that has developed and
manufactures a disposable catheter system based on its proprietary
cryoablation technology for the minimally invasive treatment of cardiac
arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System,
or the Cryoablation System, is designed to treat cardiac arrhythmias through
the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue.
The Cryoablation System has been approved in Europe for the treatment of
atrial fibrillation, and atrial flutter, the two most common and difficult to
treat arrhythmias, since 2002. In the United States, CryoCor is conducting a
pivotal trial to evaluate the safety and efficacy of the Cryoablation System
for the treatment of atrial fibrillation and the Cryoablation System has been
approved for the treatment of right atrial flutter. For more information
please visit the Company's website at http://www.cryocor.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These forward-
looking statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product development and
performance, acquisitions and integration of acquired companies, development
plans and expenditures, and our growth strategy. If our underlying
assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business strategy and may
cause actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A- Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any forward-
looking statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be based, or that
may affect the likelihood that actual results will differ from those contained
in the forward-looking statements. This cautionary statement is applicable to
all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

Media, Paul Donovan +1-508-650-8541 (office), +1-508-667-5165 (mobile);
Investor Relations, Larry Neumann, +1-508-650-8696 (office), both of Boston
Scientific Corporation